← SynDRA
VERUCERFONT
SynDRA canonical compound SYN0024890 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | CRHR1 |
|---|
| Mechanism of action | corticotropin releasing factor receptor antagonist |
|---|
All known targets
Mechanisms of action (all sources)
- CRHR1 ANTAGONIST
- Corticotropin releasing factor receptor 1 antagonist
- corticotropin releasing factor receptor antagonist
Cross-references
Synonyms
- GSK-561,679
- GSK-561679
- GSK-561679A
- GSK561679
- GSK561679A
- NBI-77860
- UNII-X60608B091
- GSK 561679A
- NBI 77860
- X60608B091
- GSK561679;3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-a]pyrimidin-7-amine
- Verucerfont [USAN:INN]
- Verucerfont (USAN/INN)
- Verucerfont,GSK561679
- SCHEMBL205309
- CHEMBL1287935
- EX-A1718
- BDBM50417503
- ZINC34661169
- SB17107
- CS-8099
- DB12512
- KB-77609
- HY-14875
- AC-30339
- D09695
- GSK 561679
- Verucerfont [USAN]
- VERUCERFONT [INN]
- VERUCERFONT [WHO-DD]
- Compound (S)-8d [PMID: 21074436]
- Compound (S)-8d (PMID: 21074436)
- verucerfontum
- RefChem:901823
- DTXCID301517015
- MFCD19443727
- NBI77860
- Verucerfont?
Look up VERUCERFONT in the interactive SynDRA portal →